Edesa Biotech is a Markham, Ontario-based biotechnology company working on non-steroidal topical treatment alternatives for inflammatory and autoimmune diseases. Edesa Biotech is a wholly owned subsidiary of Stellar Biotechnologies.
Edesa Biotech is a clinical-stage private company focused on developing treatments for dermatological and anorectal diseases. Their initial focus is on developing novel, safe and potent alternatives to steroids for allergic contact dermatitis, hemorrhoids, and anal fissures. Edesa Biotech's lead asset, EB01 is a novel non-steroidal anti-inflammatory molecule for the treatment of allergic contact dermatitis which has already demonstrated statistically significant improvements in multiple clinical studies.